EGFR protein overexpression correlates with chromosome 7 polysomy and poor prognostic parameters in clear cell renal cell carcinoma

Journal of Biomedical Science

Volumn 19, Issue 1, 2012, Pages

  Dordević, Gordana ^a   Matušan Ilijaš, Koviljka ^a   Hadžisejdić, Ita ^a   Maričić, Anton ^b   Grahovac, Blaženka ^a   Jonjić, Nives ^a  

^a UNIVERSITY OF RIJEKA   (Croatia)

^b KBC RIJEKA   (Croatia)

Author keywords

Carcinoma; Chromosome 7; EGFR; Fluorescence; In Situ Hybridization; Prognosis; Renal cell

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EGFR PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHROMOSOME 7; CHROMOSOME ABERRATION; CHROMOSOME POLYSOMY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DOSAGE; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR CELL; BIOSYNTHESIS; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; KIDNEY TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; POLYPLOIDY; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CHROMOSOMES, HUMAN, PAIR 7; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; POLYPLOIDY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84859372195     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-19-40     Document Type: Article

References (33)

1. Autocrine growth factors and cancer. Sporn MB, Roberts AB, Nature 1985 313 745 747 10.1038/313745a0 3883191 (Pubitemid 15130821)
2. EGF receptor. Wells A, Int J Biochem Cell Biol 1999 31 637 643 10.1016/S1357-2725(99)00015-1 10404636 (Pubitemid 29248872)
3. Ligand-induced receptor-mediated dimerization and activation of EGF receptor. Schlessinger J, Cell 2002 110 669 672 10.1016/S0092-8674(02)00966-2 12297041 (Pubitemid 35283957)
4. An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology. Martin V, Mazzucchelli L, Frattini M, J Clin Pathol 2009 62 314 324 10.1136/jcp.2008.059592 19052028
5. EGFR as a target for anticancer therapy-focus on cetuximab. Baselga J, Eur J Cancer 2001 37 16 S22 11597400
6. Variability in organ-specific EGFR mutational spectra in tumor epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors. Weber F, Fukino k, Sawada T, Williams N, Sweet K, Berena RM, Plass C, Caldes T, Mutter GL, Villalona-Clero MA, Eng C, Br J Cancer 2005 92 1922 1926 10.1038/sj.bjc.6602557 15841079 (Pubitemid 40826142)
7. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Ono M, Kuwano M, Clin Cancer Res 2006 12 7242 7251 10.1158/1078-0432.CCR-06-0646 17189395 (Pubitemid 46095395)
8. Are heterogeneous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation? Langner C, Ratschek M, Rehak, Schips L, Zigeuner R, J Clin Pathol 2004 57 773 775 10.1136/jcp.2003.015743 15220376 (Pubitemid 38901498)
9. EGFR FISH versus mutation: different tests, different end-points. Cappuzzo F, Lung Cancer 2008 60 160 165 10.1016/j.lungcan.2008.02.008 18367287
10. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Kawahara A, Yamamoto C, Nakashima K, Azuma K, Hattori S, Kashihara M, Aizawa H, Basaki Y, Kuwano M, Kage M, Mitsudomi T, Ono M, Clin Cancer Res 2010 16 12 3163 3170 10.1158/1078-0432.CCR-09-3239 20423982
11. EGFR targeting of solid tumors. Rocha-Lima CM, Soares HP, Raez LE, Singal R, Cancer Control 2007 14 295 299 17615536
12. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Venook AP, Cancer 2005 103 2435 2446 10.1002/cncr.21123 15880563 (Pubitemid 40800520)
13. Epidermal growth factor receptor (EGFR) signalling in cancer. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS, Gene 2006 366 2 16 10.1016/j.gene.2005.10.018 16377102 (Pubitemid 43199589)
14. Epidermal growth factor receptor and epidermal growth factor receptor therapies in renal cell carcinoma: do we need a better mouse trap? Dancey EJ, J Clin Oncol 2004 22 2975 2977 10.1200/JCO.2004.04.934 15210735 (Pubitemid 41103707)
15. Characterization of membranous and cytoplasmic EGFR expression in human normal renal cortex and renal cell carcinoma. Pu YS, Huang CY, Kuo YZ, Kang WY, Liu GY, Huang AM, Yu HJ, Lai MK, Huang SP, Wu WJ, Chiou SJ, Hour TC, J Biomed Sci 2009 16 82 (Published online 2009 September 12. doi: 10.1186/1423-0127-16- 82)
16. Epithelial growth factor receptor (EGFR) pathway and renal cell carcinoma. Ravaud A, Clermont H, Pasticier G, Smith D, Vendrely V, Maire JP, Targ Oncol 2007 2 99 105 10.1007/s11523-007-0044-7
17. Tissue microarrays: emerging standard for biomarker validation. Hassan S, Ferrario C, Mamo A, Basik M, Curr Opin Biotechnol 2008 19 19 25 10.1016/j.copbio.2007.10.009 18053705 (Pubitemid 351226513)
18. WHO Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. Lyon, France: IARC Press, Eble JN, Sauter G, Epstein JI, Sesterhenn IA, 2004 9 87
19. TNM Classification of Malignant Tumours Singapore, Republic of Singapore: Wiley-Blackwell, Sobin L, Gospodarowicz M, Wittekind C, 2009 255 258
20. Prognostic significance of morphologic parameters in renal cell carcinoma. Fuhrman SA, Lasky LC, Limas C, Am J Surg Pathol 1982 6 655 663 10.1097/00000478-198210000-00007 7180965 (Pubitemid 13234762)
21. EGF-r gene copy number changes in renal cell carcinoma detected by fluorescence in situ hybridization. Moch H, Sauter G, Gasser TC, Bubendorf L, Richter J, Presti JC Jr, Waldman FM, Mihatsch MJ, J Pathol 1998 184 424 429 10.1002/(SICI)1096-9896(199804)184:4<424::AID-PATH1223>3.0.CO;2-A 9664910 (Pubitemid 28179903)
22. Phase II trial of cetuximab in patients with refractory colorectal cancer that express the epidermal growth factor receptor. Saltz LB, Meropol NJ, Loehrer PJ, J Clin Oncol 2004 22 1201 1208 10.1200/JCO.2004.10.182 14993230 (Pubitemid 41079832)
23. The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation. Cohen D, Lane B, Jin T, Magi-Galluzzi C, Finke J, Rini BI, Bukowski RM, Zhou M, Clin Genitourin Cancer 2007 5 264 270 10.3816/CGC.2007.n.002 17553206 (Pubitemid 46867362)
24. Prognostic Impact of p53, EGFR And HER2/Neu Proteins on renal cell carcinoma. Michael A, Relph K, Havranek E, Anderson C, Polychronis A, Corbishley C, Pandha H, The Internet Journal of Urology 2006 4 http://www.ispub.com/ journal/the-internet-journal-of-urology/volume-4-number-1
25. Membranous location of EGFR immunostaining is associated with good prognosis in renal cell carcinoma. Kallio JP, Hirvikoski P, Helin H, Kellokumpu-Lehtinen P, Luukkaala T, Tammela TLJ, Martikainen PM, Br J Cancer 2003 89 1266 1269 10.1038/sj.bjc.6601241 14520458 (Pubitemid 37363415)
26. Epidermal growth factor family and renal cell carcinoma: overexpression and prognostic impact. Hofmockel G, Reiss S, Bassukas ID, Dammrich J, Eur Urol 1997 31 478 484 9187911 (Pubitemid 27234641)
27. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, J Clin Oncol 2007 25 1 118 145 17159189 (Pubitemid 350003059)
28. The expression of epidermal growth factor receptor and transforming growth factor alfa in renal cell carcinoma. Lager DJ, Slagel DD, Palechek PL, Mod Pathol 1994 7 544 548 7937720
29. Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer. Merseburger AS, Hennenlotter J, Simon P, Kruck S, Koch E, Horstmann M, Kuehs U, Küfer R, Stenzl A, Kuczyk MA, Anticancer Res 2005 25 1901 1907 16158924 (Pubitemid 40904584)
30. Targeting EGFR in bladder cancer. Zigler Villares GJ, Blehm M, Bogdan C, McConkey D, Colin D, Bar-Eli M, World J Urol 2007 25 573 579 10.1007/s00345-007-0202-7 17690890
31. Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis. Uhlman DL, Nguyen P, Manivel JC, Zhang G, Hagen K, Fraley E, Aeppli D, Niehans GA, Clin Cancer Res 1995 8 913 920
32. Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. Stumm G, Eberwein S, Rostock-Wolf S, Stein H, Pomer S, Schlegel J, Waldherr R, Int J Cancer 1996 69 17 22 10.1002/(SICI)1097-0215(19960220)69:1<17::AID-IJC4>3. 0.CO;2-Z 8600053 (Pubitemid 26083265)
33. The EGFR protein expression and the gene copy number changes in renal cell carcinomas. Lee S, An J, Kim A, Kim YS, Kim I, Korean J Pathol 2009 43 413 419 10.4132/KoreanJPathol.2009.43.5.413